4 February 2021 - Now available in Canada for the treatment of insomnia in adults.

Eisai today announced the Canadian authorisation and availability of a new non-sedative prescription medication, Dayvigo (lemborexant). 

Available in both 5 mg and 10 mg dosages, Dayvigo is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance.

Read Eisai press release